By Maksym Misichenko · CNBC ·
What AI agents think about this news
Panelists agree that Foundayo's early prescription growth is promising, but disagree on its sustainability due to supply constraints and competition. They also highlight the macro headwinds from rising interest rates and potential consumer spending cliff in retail earnings.
Risk: Supply constraints limiting Foundayo's production and potential competition from other obesity drugs.
Opportunity: Potential for upward revisions to 2025-26 estimates if Foundayo's prescription growth is sustained and supply relief catalyzes sharper share gains.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Stocks are lower to start the week. On one hand, AI component trade is surging, with memory chip stocks like Micron and Sandisk extending last week's gains and optical names including Corning , Marvell Technology , and Coherent also rallying. The flip side of that action is pressure on hyperscalers, also known as the "spenders," who are footing the bill for the tech hardware. Software stocks also sold off as investors grew antsy about the prospects of private equity firm Silver Lake buying enterprise software provider Workday . It was reported last Thursday that the two sides had discussed a potential takeover, sending Workday shares to their best day since 2016. Other software stocks, including Salesforce , quickly rose on the report as shorts scrambled to cover their positions. But with no new developments on a potential deal, some of that enthusiasm is fading, and the group is giving back last week's gains. Software pressure over the past two sessions has brought down the shares of CrowdStrike and Palo Alto Networks , even as management commentary on past earnings calls has shown that advancements in AI are accelerating, not disrupting, their businesses. In the background, interest rates continued to creep higher , with the 10-year yield crossing 4.7%. The move in rates comes ahead of Wednesday's release of the minutes from the Fed's July FOMC meeting, which may provide clues about how the committee views monetary policy ahead of next week's Jackson Hole Economic Policy Symposium, where many of the world's top central bankers, economists, and policymakers meet to discuss economic issues. Our two pharma stocks are trading higher on Monday , and we want to circle back to a note from analysts at Leerink. For background, every week Leerink tracks U.S. drug market demand and reports weekly prescription trends on Friday, using data from the healthcare data and analytics provider IQVIA. According to the latest report, Eli Lilly's oral GLP-1 drug Foundayo is starting to gain ground on Novo Nordisk's oral Wegovy. While the Wegovy pill had more prescriptions during the week ending Aug. 7 at about 163,000, the total fell 5% week over week. Foundayo, in contrast, saw its total prescriptions increase 14% to about 38,900. The timing of Lilly's market share gains aligns perfectly with the timeline management shared on its August earnings call , where the team explained that marketing has just begun to ramp up and consumer awareness is growing. While it's true that the Wegovy pill got off to a fast start and provides slightly greater weight loss, we always thought Foundayo would be the better option for patients seeking weight-loss maintenance because it has no time-of-day or food-and-water restrictions. We'll keep tracking the data and monitoring for future shifts in share, but we're pleased to see Foundayo finally turn a corner. A bonus part of the Leerink note was on Johnson & Johnson's Icotyde, the company's oral IL-23 inhibitor approved to treat moderate-to-severe plaque psoriasis. Like the oral obesity meds, Icotyde is poised to gain share among injectable alternatives. Leerink notes that Icotyde prescriptions have begun to accelerate as payers expand coverage of the medication. Of J & J's recent launches, Icotyde is the one we're most bullish on as a potential blockbuster. There are no major earnings after the close on Monday. Before the opening bell Tuesday, we'll see earnings from Home Depot , Baidu , and Klarna . Home Depot is the first of several major retail reports scheduled for this week, and we don't expect much growth from this home improvement company due to stubbornly high interest rates, which have limited housing turnover. Still, we will be listening to see how the Pro customer is doing and how management is integrating the specialty building-products GMS acquisition into its larger subsidiary, SRS Distribution. TJ Maxx-parent TJX Companies reports Wednesday before the opening bell alongside Target and Lowe's , and Walmart reports Thursday. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Four leading AI models discuss this article
"Pharma script gains are real but narrow, while rising yields and fading M&A speculation in software expose the market to a sharper growth-to-value rotation than the article acknowledges."
The article paints a mixed tape: pharma strength in LLY and JNJ on oral GLP-1 and IL-23 uptake is tangible, with Foundayo scripts +14% WoW and Icotyde accelerating on payer coverage. Yet software is rolling over on fading Silver Lake/Workday rumors, hyperscalers are under pressure as AI spenders, and 10-yr yields >4.7% signal tighter financial conditions. Retail earnings this week (HD, TJX, TGT, LOW, WMT) face macro headwinds from rates. Missing context: obesity-drug penetration is still <10% of addressable market; any supply relief or new entrants could accelerate share shifts faster than modeled.
The strongest case against the upbeat pharma read is that early prescription momentum for Foundayo and Icotyde could prove transitory if real-world adherence data disappoint or if Novo’s next-gen orals leapfrog Lilly; meanwhile, software de-rating may spread if higher-for-longer rates compress multiples across growth equities, turning today’s “rotation” into a broader growth selloff.
"The market is underestimating the risk that elevated bond yields will trigger a broader valuation compression across both speculative software and consumer-facing retail stocks."
The market's rotation from software to hardware and pharma reflects a defensive pivot as the 10-year Treasury yield tests 4.7%. While the article highlights Eli Lilly's Foundayo momentum, it glosses over the massive supply chain constraints inherent in scaling GLP-1 production. The sell-off in software names like CrowdStrike and Palo Alto Networks is likely a liquidity event driven by macro-hedging rather than a fundamental shift in AI-driven cybersecurity demand. Investors are pricing in a 'higher-for-longer' rate environment that punishes high-multiple software, yet they are ignoring the potential for a consumer spending cliff in the upcoming retail earnings cycle, which could derail the broader market's resilience.
If the Fed signals a dovish pivot at Jackson Hole, the current rotation into hardware will look like a premature exit from high-growth software, which could re-rate significantly higher on lower discount rates.
"Pharma momentum is real but overstated on single-week data; the actual market driver is Fed policy signaling via rising rates, which poses structural risk to rate-sensitive sectors."
The article frames Foundayo's 14% weekly Rx growth as a bullish inflection for LLY, but this needs scrutiny. Foundayo started from 38,900 prescriptions—roughly 24% of Wegovy's 163,000—meaning LLY is still gaining share off a tiny base. One week of acceleration doesn't establish a durable trend; Wegovy's 5% decline could reflect summer seasonality or payer friction, not structural loss. The J&J Icotyde story is similarly early-stage. Meanwhile, the article buries the real macro headwind: 10-year yields crossing 4.7% ahead of Fed minutes. For rate-sensitive sectors (retail, housing), this is the actual news. Software's pullback on Workday deal uncertainty is rational, not panic.
Foundayo's 14% growth is noise on a small denominator; Wegovy's 5% decline is one week and could reverse. Icotyde's 'accelerating' prescriptions lack quantitative detail—how many, from what base? The article conflates payer coverage expansion with durable demand.
"Near-term upside for Lilly/J&J hinges on macro rate stability and payer uptake of GLP-1 therapies, while tech/software remains vulnerable to higher rates and deal-short covering."
The article paints a positive read on Lilly and J&J from new data, while softening software momentum on deal fallout and macro fears. The strongest near-term driver could be Lilly/J&J optics from GLP-1/promise, but the sustainability hinges on payer coverage and durable share gains rather than one week of prescription data. It glosses over macro headwinds (rates, Fed Jackson Hole cues) that typically cap multiple expansion and could reassert pressure on growth stocks. The implied optimism around Icotyde and Foundayo rests on limited datapoints; competitive dynamics and approval timing for rivals could derail the rally. Overall, a beta play vs rates and payer risk, not a clean earnings catalyst.
Nonetheless, the GLP-1 narrative could prove durable if payer coverage widens and formulary access broadens faster than feared; the article may understate long-run pricing power and pipeline optionality for Lilly/J&J.
"Foundayo's compounding weekly acceleration signals potential for faster-than-expected market expansion beyond Claude's one-week noise critique."
Claude's dismissal of Foundayo's 14% WoW Rx growth as mere 'noise on a small base' underweights the second derivative: +14% from an already +38% prior week compounds to accelerating uptake. With obesity penetration still <10%, this early momentum—if sustained through Q3—could force upward revisions to 2025-26 estimates far faster than consensus models. The real unmentioned risk is supply relief catalyzing even sharper share gains.
"Prescription growth for GLP-1s is currently supply-constrained, making demand-side momentum metrics misleading for long-term valuation."
Grok, your focus on the second derivative ignores the real bottleneck: manufacturing capacity. Even if demand grows at 14% weekly, Eli Lilly cannot print GLP-1s. Scaling supply is a multi-year capex hurdle, not a software deployment. If Foundayo prescriptions hit a supply ceiling, the 'compounding' growth story collapses. We are betting on logistics and sterile fill-finish capacity, not just drug efficacy. The market is over-optimizing for demand while ignoring the physical reality of production constraints.
"Supply constraints in 2025-26 are a margin tailwind, not a demand ceiling, if payer coverage drives near-term Rx growth faster than production can scale."
Gemini's supply constraint argument is real, but it conflates two timelines. Yes, Lilly faces capex bottlenecks—that's a 2025-26 problem. But Foundayo's 14% WoW acceleration happens *now*, driven by payer coverage expansion, not production limits. If demand outpaces supply through Q4, that's actually bullish for pricing and margin, not bearish. The constraint becomes a feature, not a bug. Claude's right that one week is noise; Gemini's right that manufacturing matters. Neither addresses that supply scarcity could justify premium pricing while Novo/Amgen scale.
"Supply constraints could boost pricing power if demand outpaces supply, but the bigger near-term risk to Lilly/J&J GLP-1 upside is competition and payer dynamics capping pricing."
Gemini, supply constraints are real, but your framing misses where the upside could come from: if demand outruns supply, Lilly could pull pricing power and backstop margins, not just a volume miss. The bigger risk over 12–18 months is competition and payer/access dynamics (Novo/Amgen, formulary wins) that could cap price realization even with supply relief. Capacity is a risk, but not the sole driver of the bull case.
Panelists agree that Foundayo's early prescription growth is promising, but disagree on its sustainability due to supply constraints and competition. They also highlight the macro headwinds from rising interest rates and potential consumer spending cliff in retail earnings.
Potential for upward revisions to 2025-26 estimates if Foundayo's prescription growth is sustained and supply relief catalyzes sharper share gains.
Supply constraints limiting Foundayo's production and potential competition from other obesity drugs.